Branched Chain Fatty Acids In The Neonatal Gut, And Estimated Prevalence In The American Food Supply by Ran-Ressler, Rinat
  
 
BRANCHED CHAIN FATTY ACIDS IN THE NEONATAL GUT, AND 
ESTIMATED PREVALENCE IN THE AMERICAN FOOD SUPPLY 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy  
 
 
 
 
 
by 
Rinat Rivka Ran-Ressler 
January 2011
  
 
 
 
 
 
 
 
 
 
 
 
© 2011 Rinat Rivka Ran-Ressler
  
BRANCHED CHAIN FATTY ACIDS IN THE NEONATAL GUT, AND 
ESTIMATED PREVALENCE IN THE AMERICAN FOOD SUPPLY 
 
Rinat Rivka Ran-Ressler, Ph. D.  
Cornell University 2011 
 
Branched chain fatty acids (BCFA) are found at trace levels in most non-ruminants, 
but are major components of vernix. Vernix suspended in amniotic fluid is normally 
swallowed by the fetus, increasingly so as parturition approaches. The first study 
investigated whether BCFA are a component of the newborn gut by measuring BCFA 
distribution in vernix and meconium of newborns. Results indicated that BCFA are 
normal constituents of the term newborn gastrointestinal (GI) tract. Furthermore, 
differences found in the BCFA distribution between vernix and meconium suggest that 
the fetal gut metabolizes BCFA. 
Given that BCFA are constituents of the newborn GI tract, the second study examined 
whether lack of GI exposure to BCFA, due to premature birth, is associated with the 
risk for necrotizing enterocolitis (NEC). Rat pups fed rat milk formula with BCFA had 
less NEC compared to pups fed a standard formula. A three-fold increase in the ileal 
anti-inflammatory, IL-10, was also detected in the BCFA-fed group. BCFA were 
selectively incorporated into ileum phospholipids. These results indicate that BCFA 
have a protective effect against NEC and that this effect may be due to increased ileal 
anti-inflammatory cytokine levels. This suggests that BCFA are metabolized in the 
ileum, where they may be associated with the reduction in NEC.  
As data on possible beneficial roles of BCFA emerge, their presence in the US food 
chain becomes valuable. The third study examined BCFA distribution in retail milk  
 a major contributor to energy intake among most segments of the population. BCFA 
were found to comprise 2% of the total FA in retail milkfat and estimated intake 
suggests that BCFA can constitute a substantial amount of daily fat intake.   
These studies indicate that BCFA are normally present in the human gut throughout 
the life cycle and may be beneficial to human digestive health. They are native to the 
American diet and appear to help maintain perinatal gut health. These results invite 
continued consideration of the health effects of BCFA in human nutrition, and 
particularly inclusion in preterm infant formula.  Their estimated intake in the 
American diet suggests that future studies explore their possible health benefits. 
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CHAPTER 1 
 
BRANCHED CHAIN FATTY ACIDS ARE CONSTITUENTS 
OF THE NORMAL HEALTHY NEWBORN GASTROINTESTINAL TRACT*
1
 
 
Abstract 
Vernix suspended in amniotic fluid is normally swallowed by the late term fetus. We 
hypothesized that branched chain fatty acids (BCFA), long known to be major vernix 
components, would be found in meconium and that the profiles would differ 
systematically.  The objective of the study was to investigate the presence of BCFA in 
meconium and to characterize their relative profiles in both vernix and meconium. 
Vernix and meconium were collected from term newborns and analyzed.   BCFA-
containing lipids constituted about 12% of vernix dry weight, and were predominantly 
saturated, and had 11 to 26 carbons per BCFA.  In contrast, meconium BCFA had 16 
to 26 carbons, and were about 1% of dry weight.  Meconium BCFA were mostly in 
the iso- configuration, whereas vernix BCFA contained dimethyl and middle chain 
branching, and five anteiso -BCFA.   The mass of BCFA entering the fetal gut as 
swallowed vernix particles is estimated to be 180 mg in the last month of gestation 
while the total mass of BCFA found in meconium is estimated to be 16 mg, thus most 
BCFA disappear from the fetal gut.  The BCFA profiles of vernix and meconium show 
that BCFA are major components of normal healthy term newborn gastrointestinal 
tract.  BCFA are candidates for agents that play a role in gut colonization and should 
be considered a nutritional component for the fetus/newborn. 
 
* Ran-Ressler RR, Devapatla S, Lawrence P, Brenna JT 2008 Branched chain fatty are 
constituents of the normal healthy newborn gastrointestinal tract. Pediatr Res 64:605-609. 
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Introduction 
Branched chain fatty acids (BCFA) are mostly saturated fatty acids (SFA) with one or 
more methyl branches on the carbon chain. The structure of the predominant 
monomethyl BCFA of the iso- and anteiso-configuration is shown in Figure 1.1.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Structures of representative branched chain fatty acids (BCFA).                
n- (normal) hydrocarbon chains are straight with no branching.  iso-BCFA have a 
bifurcated methyl branch.  The systematic name for iso-15:0 is 13-methyl 
tetradecanoic acid. anteiso-BCFA have a methyl branch on the antepenultimate 
carbon.  anteiso-15:0 is 12-methyl tetradecanoic acid. 
 
BCFA are synthesized mainly by the skin and have long been known to be a major 
component of vernix caseosa (10-20% dry weight) (1).  Among terrestrial animals, 
vernix is unique to humans, and is not found in other land mammals, including other 
primates (2). Vernix is made of sebum and fetal corneocytes (1, 3) and is produced by 
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fetal skin starting at 24 weeks gestational age and continuing until term birth (4). 
During the third trimester vernix sloughs off as particulates that become suspended in 
amniotic fluid (3, 5), possibly aided by lung surfactant phospholipids that also enter 
the amniotic fluid.  The fetus normally swallows amniotic fluid in amounts 
approaching 500 ml at the end of gestation (6, 7) and with it vernix.  Thus, the late 
term fetal gut is normally exposed to vernix and its BCFA, increasingly so as 
parturition approaches. 
 
Vernix dry matter is composed of approximately equal amounts of protein and lipids 
(2, 8). Lipid fractions in vernix have been comprehensively characterized (9-11) and 
shown to be 25-30% sterol esters (SE), 18-36% triglycerides (TAG), 12-16% wax 
esters (WE), 9% squalene, 5% ceramides, and low levels of non-esterified fatty acid 
(NEFA) fraction was also detected by some (10, 12) but not by others (13).   BCFA 
are found in all acyl-carrying lipid classes, WE (16-53%) and SE (27-62%) (9-11, 13), 
as well as in the TAG (18-21%) and NEFA (21%) fractions  (10).  
 
Apart from skin (1, 9, 14), BCFA are at very low levels in internal tissue (14), but are 
also found in human milk (15-17) at concentrations as high as 1.5%w/w of total fatty 
acids (FA).  This level is comparable to and in some cases greater than that of 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (ARA, 20:4n-6) in the 
same milk. For instance, a 1981 publication reported the concentration of anteiso- 
17:0 in Australian women’s colostrum to be 0.45%w/w of total FA, exceeding the 
concentrations of DHA (0.32%w/w) and ARA (0.4%w/w) (17). 
 
Meconium, the newborn’s first fecal pass, first appears in the fetal GI tract at around 
12 weeks of gestational age, and is normally passed after birth (18-20).  It consists of 
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amniotic fluid residue, skin and gastrointestinal (GI) epithelial cells, GI secretions and 
enzymes, lipids, sugars, proteins, cholesterol, sterols, bile acid and salts (18, 19, 21, 
22). Meconium contains 12% dry weight lipid (21), and there is only one unconfirmed 
study reporting BCFA in meconium (23).  There are no studies linking BCFA 
composition of vernix and meconium in the same infants.  
 
We hypothesized that vernix BCFA of term newborns would survive the alimentary 
canal and be found in meconium.  Our test of this hypothesis led us to characterize the 
relative BCFA profiles of vernix and meconium to establish the degree to which the 
profile is altered by the sterile fetal gut in utero.   
 
 
Methods 
This study was approved by the Cornell University and the Cayuga Medical Center 
Institutional Review Boards (IRB) on the Use of Human Subjects.   The IRB approved 
an exemption from the requirement to obtain individual informed consent because the 
human materials sampled, vernix and meconium, are deemed to be medical waste and 
no individually identifiable information was obtained from participants. 
Sample collection. Eighteen samples of vernix and meconium were collected from 18 
normal term newborns at Cayuga Medical Center in Ithaca, NY. Vernix was removed 
from the shoulder regions in the birthing room, placed in clean tubes and stored at -
80°C until analysis. Meconium was collected from diapers and similarly transferred 
into clean tubes and stored at -80°C until analysis.  
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FA analysis. Total lipids were extracted from the vernix and the meconium samples 
according to a modified Bligh and Dyer method (24).  Fatty acids are overwhelmingly 
found in mammalian pools, such as vernix and meconium, as acyl moieties which are 
constituents of higher molecular weight lipid molecules such as TAG, SE, and WE.  
For detailed molecular analysis, fatty acyl groups are hydrolyzed and fatty acid methyl 
esters (FAME) synthesized for analysis.  FAME were prepared using 14% BF3 in 
methanol (Sigma Chemical, St. Louis, MO.). Butylated hydroxytoluene (BHT) was 
added to methanol as an antioxidant. Heptadecanoic acid (Sigma Chemical, St Louis, 
MO) in chloroform was used as an internal standard. This routine step obscures 
heptadecanoic acid which is normally rare in mammalian tissue but is present in 
vernix and meconium. Because of the extraordinary diversity of FA in these samples, 
any internal standard interferes with analysis of one or more FA in some of the 
samples. A correction was applied to estimate the extent of interference, and the 
signals were carefully calibrated against external standards. 
 
FAME analyses were performed using a Hewlett Packard 5890 series II gas 
chromatograph (GC).  A BPX-70 column (60m×0.32mm×0.25μm, SGE, Austin, Tx) 
was used for the analysis with H2 as the carrier gas.  FAME identities were determined 
by a chemical ionization (CI) and electron impact (EI) mass spectrometry (MS), using 
a Varian Star 3400 GC coupled to a Varian Saturn 2000 ion trap MS. BCFA FAME 
identities were based on GC retention time of each substance and its electron impact 
mass spectra.  FAME mass spectral assignments were confirmed by conversion of the 
FAME to picolinyl ester derivatives according to the method described by Christie 
<www.lipidlibrary.co.uk> and Yang (25), followed by GC/MS analysis and 
comparison to literature spectra (26-31). 
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An equal weight FAME mixture (68A; Nuchek Prep, Elysian, MN) was used to 
calculate response factors. The following were also used as standards: n-11:0 up to 
n-24:0 (Nuchek Prep, Elysian, MN); iso- 13:0, anteiso- 13:0, iso- 15:0, anteiso- 15:0; 
iso- 17:0, anteiso- 17:0 (Larodan Fine Chemicals AB, Malmo, Sweden) and 10 methyl 
hexadecanoic acid (Matreya LLC, Pleasant Gap, PA).   FA levels were expressed as 
weight % of total fatty acids for all 11 to 32 carbons FA.   
 
Statistics. Data are expressed as mean±SD for study population characteristics, and as 
mean±SEM for FA analysis. Statistical analyses were made using JMP 6 (SAS 
Institute, Cary, NC). Differences in mean of each FA were calculated using one 
sample t-test for non-zero differences, with p<0.05 declared significant. 
 
 
Results 
Subjects.  Characteristics of the study population are presented in Table 1.1.  No 
complications were present for any of the newborns other than as noted.  All but two 
newborns were by vaginal delivery.  Six mothers received antibiotic treatment during 
pregnancy; five of them gave birth to female infants.  
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       Table 1.1. Characteristics of study population 
 
 Mean ± SD Range 
Mother’s age (years) 29±5.8 18-42 
Gestational age (weeks) 40±1 38-41 
Birthweight (kg) 3.3±0.5 2.3-4.4 
Gender 10 females, 8 males 
Delivery 16 vaginal, 2 CS* 
Antibiotics 5 females, 1 male 
     * Cesarean section 
 
 
Overall FA distribution.  A profile of FA classes is shown in Table 1.2.  Comparisons 
of all classes were significant at the p<0.05 level.  BCFA constituted almost a third 
(29.1±1.5%w/w) of all FA in vernix and were significantly higher compared to the 
mean levels in meconium (17.5±1.3%w/w; p<0.05).  This drop in BCFA was 
accompanied by a reciprocal increase in normal (n-) saturated FA (n-SFA) 
specifically, 34±1.9%w/w in vernix and 51.3±3.0%w/w in meconium (p<0.05).  
Differences in n-monounsaturated fatty acids (MUFA) and polyunsaturated fatty acid 
(PUFA) were modest by comparison.   
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Table 1.2. Profile of fatty acid classes (%w/w) in vernix and meconium (mean±SEM) 
 
FA Vernix Meconium 
BCFA 29.1±1.5* 17.5±1.3 
n-SFA 34±1.9* 51.3±3.0 
n-MUFA 31.0±1.7* 22.4±2.1 
PUFA 3.9±0.4* 7.1±1.1 
*p<0.05 
 
 
Overall, BCFA hydrolyzed from their native lipid classes constituted 5.8% of dry 
weight of vernix, corresponding to approximately 12% of dry weight of vernix within 
the native BCFA-containing lipids.  Meconium had 0.55% dry weight of hydrolyzed 
BCFA and an estimated 1% of BCFA-containing lipids. 
 
BCFA distribution in vernix and meconium.  Figure 1.2 is a graphical summary of 
the BCFA profiles for vernix and meconium for those BCFA detected in samples from 
at least 3 newborns, presented left to right in order of carbon number.  In total, 30 
BCFA were identified in vernix while nine were also detected in meconium.  Vernix 
BCFA ranged from 11 to 26 carbon atoms and were primarily saturated apart from 
two iso- monounsaturates.   Iso- BCFA, anteiso- BCFA, middle chain monomethyl 
9 
BCFA and dimethyl BCFA were all detected among vernix BCFA.  In contrast, 
meconium BCFA had a much more restricted range of carbon numbers, from 16 to 26 
carbons.  Of the nine meconium BCFA, eight were iso- BCFA, of which two were 
MUFA, and one was anteiso. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Branched chain fatty acid (BCFA) methyl ester profiles for vernix and 
meconium (means ± SEM, n<18 newborn) listed left to right in order of molecular 
weight. Means are for those FA appearing in samples from at least three newborns.  
iso-BCFA have a dimethyl terminal structure:  iso-16:0 is synonymous with 14-
methyl-15:0 (14-methyl-pentadecanoic acid).  anteiso-BCFA have a methyl branch at 
the n-2 position:  anteiso-17:0 is synonymous with 14-methyl-16:0 (14-methyl-
hexadecanoic acid).  i=iso; ai=anteiso; Me=methyl; diMe =  two methyl branches.   
Key: □  vernix; ■  meconium.    *p<0.05 
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The profile of the iso- BCFA in vernix and meconium is shown in Figure 1.3.  The 
vernix iso- BCFA profile had odd and even carbon numbered FA from iso-12:0 to iso-
16:0, and only even carbon numbers at greater chain lengths.  In contrast, meconium 
iso BCFA was dominated by the shortest chain BCFA in its profile, iso-16:0, which 
was more than twice the relative concentration of any other BCFA.  Five of the eight 
iso-BCFA appearing in both vernix and meconium were a significantly different 
proportion of BCFA in the respective profiles; the preponderance of longer chains in 
meconium lead to significant differences in three of the four iso-BCFA of chain 
numbers from 20 to 26 carbons. 
 
 
 
 
 
 
 
 
 
Figure 1.3. iso- Branched chain fatty acid (BCFA) methyl esters in vernix and 
meconium (means ± SEM, n<18 newborn) listed left to right in order of molecular 
weight.  i=iso.  Key:  □  vernix; ■  meconium.   *p<0.05 
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The profile of anteiso- BCFA is shown in Figure 1.4.  All five anteiso- BCFA 
detected in vernix are odd carbon numbered.  They range from 13 to 25 carbons, and 
only one, anteiso-17:0, is found in meconium. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. anteiso- Branched chain fatty acid (BCFA) methyl esters in vernix and 
meconium (means ± SEM, n<18 newborn) listed left to right in order of molecular 
weight. ai=anteiso. Key:  □  vernix; ■  meconium.   *p<0.05 
 
 
 
Figure 1.5 is a graphical summary of the straight chain, n-FA, profiles for vernix and 
meconium. Vernix normal FA had 11 to 26 carbon atoms, and meconium FA had 14 
to 26 carbons, and both contained small amounts of odd chain number FA.  Again, 
meconium BCFA tended to be of greater molecular weight.   
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Figure 1.5.  Normal (straight chain) fatty acid methyl esters in vernix and meconium 
(means ± SEM, n<18 newborn) listed left to right in order of molecular weight.  
Key:  □  vernix; ■  meconium.    *p<0.05.  
 
 
 
Discussion 
The presence of BCFA in both vernix and meconium of healthy term infants indicates 
that BCFA are a major component of gut contents of normal term newborns, and their 
presence in meconium implies that they are present throughout the length of the gut.  
As such, BCFA are a component of the GI tract milieu present when the first few 
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shift in BCFA profiles to high molecular weights, as well as the absence of most 
BCFA other than iso-BCFA, indicates that the fetal alimentary canal readily absorbs 
and metabolizes most BCFA. 
 
There are many reports of BCFA in breastmilk, with the earliest and most extensive, 
showing 54 BCFA with a cumulative concentration of 1.5%w/w (16).  A 1981 paper 
measured the concentration of BCFA in mature Australian breast milk to be a total of 
0.84%w/w and one BCFA, anteiso-17:0 in colostrum at 0.45%w/w of fatty acids, 
exceeding the concentrations of DHA (0.32%w/w) and ARA (0.40%w/w) in the same 
mother’s mature breastmilk  (17).  Chen reported four BCFA with a cumulative 
concentration of 0.58%, w/w in Canadian breastmilk (32).  A study of California 
women yielded an average of 0.60% BCFA for the four BCFA that were reported 
(15:0, 16:0, 17:0, 18:0, branch location not reported) (33).  Corso found six BCFA in 
milks of 40 women in southern Italy (34), with anteiso-17:0 ranging from 0.12 to 
0.93% of total fatty acids.  This variability is not unlike that for DHA; breastmilk 
DHA ranges between 0.06%w/w and 1.40%w/w (35).  Many, but not all, breastmilk 
fatty acid concentrations are closely linked to the dietary intake of the fatty acid or its 
precursor, including DHA to which the wide reported range is ascribed (35).  It is most 
likely that the absence of BCFA identification in most breast milk FA papers is due to 
their low concentration, their appearance in a GC trace amidst the major saturates and 
monounsaturates in the chromatogram, and the historical absence of a compelling 
metabolic role for them. 
 
The exposure of the gut to BCFA in utero, and possibly from breastmilk, is greater 
than any other period of life because BCFA are at trace levels in normal foods.  The 
unique niche represented by BCFA and other components in the human gut may be 
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important for establishing commensal bacteria during colonization.  BCFA are 
prominent membrane components of many bacterial species (36, 37).  For instance, 
BCFA constitute 95% of the FA in several bacilli and lactobacilli, including 
Sporolactobacillus inulinus, which has very recently been shown to be a probiotic 
candidate (37).  The FA of nine Bifidobacterium strains include BCFA such as iso-
14:0, anteiso-15:0, iso-16:0 and iso-18:0 at various levels (0.6-24.6%w/w).  iso-14:0 is 
the second most abundant FA in Bifidobacterium breve with levels as high as 
24.6%w/w (38). It is reasonable to hypothesize that the presence of BCFA in the 
neonatal gut would alter the mix of dominant species, favoring those organisms that 
use BCFA in their membranes, and we postulate that BCFA are a unique feature of the 
human fetal gut favoring the growth of commensal bacteria during colonization.  
 
This hypothesis has implications for colonization of the GI tract of very premature 
infants, and may be a factor in the development of necrotizing enterocolitis (NEC), the 
etiology and pathogenesis of which is not well understood (39, 40).  NEC is one of the 
major causes of morbidity in premature infants (39) though it is certainly related to 
pathogen overgrowth (41).  Leading hypotheses with empirical support are that NEC 
is related to prematurity, enteral feeding, and bacterial colonization (40).  Importantly, 
it has not been observed prenatally.  NEC risk is higher among lower gestational age 
infants and is rare in term infants (42).  Breast milk consumption is associated with a 
lower incidence of NEC (40, 43).  Although no specific pathogenic bacteria has been 
associated with NEC (43), supplementation of premature animals and infants with 
probiotic strains appear to reduce its incidence (39, 44).  With these considerations, we 
hypothesize that BCFA have a role in enhancing proper GI colonization: vernix begins 
to appear around week 24 of gestation and accumulates as particulates in amniotic 
fluid toward term (3) thus, the GI tract of very premature infants is not exposed to 
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vernix BCFA prenatally.  Postnatally they would be exposed to BCFA if breastfed, but 
formula-fed preterms would not be exposed to BCFA since they are not a component 
of preterm formulas.  Finally, we note that the incidence of NEC drops as gestational 
age approaches normal term, therefore later term premature infants would be exposed 
to some BCFA and may benefit if the hypothesis is correct. 
 
We can estimate the mass of BCFA entering and exiting the alimentary canal.  At 
term, amniotic fluid lipids are about 154 mg/L (45), of which about 52 mg/L are 
phospholipids that are likely to originate as BCFA-free lung surfactant (3, 10).   Thus, 
the amniotic fluid vernix lipids concentration is about 102 mg/L.  Of this, our 
measurements indicate that 57% are FA, to yield 58 mg/L.  Our data (Table 2) further 
indicate that 29% are BCFA, to yield 17 mg/L BCFA.  The fetus is estimated to 
swallow 200 to 500 ml/day of amniotic fluid near term (46, 47), and taking the 
midpoint of this range, 350 ml/day, 6 mg BCFA per day enter the fetal GI tract 
amounting to 30×6 = 180 mg BCFA in the last month of gestation.  Meconium is the 
output of the GI tract integrated from about 12 weeks gestation.  Total meconium for 
27 term infants was reported (48) to be 8.9 g wet weight, averaging 32% dry weight, 
or 2.8 g.  Our data indicate that about 0.55% is BCFA, or about 16 mg average total 
BCFA in meconium.  This value is an order of magnitude lower than our estimate of 
the BCFA swallowed in the last month of gestation, and suggests that most of the 
BCFA disappear during transit.  The distribution and structural characteristics of 
BCFA that do appear in meconium reflect processing of vernix by the enterocytes.  
Our data show that C12-15 BCFA, as well as nearly all BCFA apart from iso-BCFA, 
are absent from meconium and thus must have been metabolized.  The nature of this 
metabolism remains to be determined, in part because BCFA and their interaction with 
human enterocytes have not been studied.   
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Chain elongation is one likely metabolic transformation that would explain the 
absence of C12-15 BCFA, and preponderance of longer chain BCFA, in meconium.  
Suggestive evidence in support of this hypothesis is found in the data of Figure 1.  The 
significantly greater level of meconium iso-16:0 compared to vernix iso-16:0, is 
roughly the sum of vernix iso-14:0 and iso-16:0, consistent with the hypothesis that 
elongation of vernix iso-14:0 adds to the existing iso-16:0.  Similar observations apply 
to meconium iso-20:0 and vernix iso-18:0 and iso-20:0.   
 
Medium chain fatty acids (C8-C14) are commonly fed to premature infants because 
they are efficiently absorbed through the gastric mucosa, directly transported to the 
liver via the portal vein, and oxidized by the immature GI tract.  Although the BCFA 
with 15 or fewer carbons are absent from meconium, Figure 1.4 shows that the FA    
n-14:0 and n-15:0 are partially excreted.  This observation implies that there is 
selective uptake and retention of BCFA by the fetal GI tract that may not operate as 
efficiently for the n-FA. 
 
Our measurements of BCFA are in line with previous data.  BCFA constituted almost 
one third of all FA in vernix (11, 49), and the levels of vernix SFA, MUFA and PUFA 
were within the range encompassed by previous reports (10, 49, 50).  We found only 
odd numbered carbon anteiso BCFA, consistent with some previous reports (49-51), 
but not with others (10, 11).   BCFA averaged 17%w/w of all FA in meconium in our 
samples.  The single previous study showing BCFA in meconium reported only on the 
free fatty acid fraction and used GC with retention time matching for identification.   
iso FA with 22 and 24 carbons were identified at 4%w/w and 6%w/w respectively, 
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and nine other iso-BCFA were tentatively assigned (C14-21, 25) with no percent 
fraction provided.   
 
Though five anteiso- BCFA were detected in vernix, anteiso-17:0 was the sole 
anteiso-BCFA detected in meconium, and there is no obvious explanation as to why 
this was the case.   Weanling rats fed 100mg/week anteiso-17:0 in an otherwise fat 
free diet excreted 8-10% in the feces and stored a similar amount in adipose tissue 
(52), and apparently also converted a small amount to anteiso-15:0.  The remaining 
80% was metabolized to substances other than anteiso- FA.   The levels of anteiso-
17:0 have been reported to be the highest among all BCFA in at least one study of 
breastmilk (17), and it is notable that anteiso-17:0 is a major lipids constituent of 
many bacterial membrane (36).  
 
The combined levels of the middle chain monomethyl and dimethyl BCFA in our 
vernix samples were similar to the levels reported in a single vernix sample by 
Nicolaides & Apon (49).  In our sample of 18 newborns, the average proportions of 
dimethyl monomethyl BCFA dominated over middle chain monomethyl BCFA.  The 
first methyl branch in the dimethyl BCFA was located predominantly on the fourth 
carbon of the chain, consistent with previous findings (49, 50).  However, in our study, 
the second methyl branch in half of the dimethyl BCFA was located on an odd 
numbered carbon, and in almost all the dimethyl BCFA, this methyl branch was 
located on the anteiso carbon of the FA chain.  
 
 
In summary, there are dramatic and systematic differences in BCFA composition 
between vernix and meconium, indicating that BCFA are actively metabolized in the 
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fetal GI tract.  This observation implies that vernix should be considered a nutritional 
agent, and that BCFA are a normal and quantitatively substantial component of the 
normal term newborn GI tract.  Further studies are warranted to understand the uptake 
and metabolism of BCFA by enterocytes, and the role of BCFA during bacterial 
colonization.  The absence of vernix, and BCFA, in the GI tract of very premature, 
formula-fed infants may have a role in the etiology of NEC, among the most 
devastating conditions facing the preterm infant. 
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CHAPTER 2 
 
BRANCHED CHAIN FATTY ACIDS REDUCE THE INCIDENCE OF 
NECROTIZING ENTEROCOLITIS IN A NEONATAL RAT MODEL*
1
 
 
Abstract 
Branched chain fatty acids (BCFA) are major components of vernix caseosa. Vernix 
suspended in late gestation amniotic fluid is swallowed by the fetus, and BCFA are 
found as normal components of the newborn gastrointestinal (GI) tract.  We tested the 
hypothesis that premature infant lack of GI BCFA exposure could be linked to the risk 
for necrotizing enterocolitis (NEC) in an established animal model.  Three groups of 
premature rats were dam-fed (DF), or hand fed either a rat milk substitute (NEC) or a 
rat milk substitute with 20% w/w BCFA (BCFA).  All groups were exposed to 
asphyxia and cold stress to develop NEC. Intestinal injury, cytokines and mucins gene 
expression, and ileal BCFA uptake were evaluated. NEC incidence was reduced by 
more than 50% in the BCFA group compared to the NEC group as assessed in ileal 
tissue.  BCFA were selectively incorporated into ileal phospholipids.  IL-10 mRNA 
was increased 3-fold in the BCFA group compared to the NEC group, and no other 
inflammatory or mucosal mRNA markers were altered. These data indicate that BCFA 
reduce NEC incidence, and are consistent with the hypothesis that the effect is at least 
in part mediated by enhanced IL-10 by BCFA.  
 
*Ran-Ressler RR, Khailova
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Dvortak, B  Branched chain fatty acids reduce the incidence of necrotizing enterocolitis in a 
neonatal rat model. Submitted to the Pediatric Research, August 2010. 
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Introduction 
Branched chain fatty acids (BCFA) are primarily saturated fatty acids (SFA) with one 
or more methyl branches on the carbon chain. In mono-methyl BCFA, most methyl 
branching is at the penultimate (iso) or antepenultimate carbon (anteiso) as shown in 
Figure 1.1  In humans, BCFA are synthesized mainly by the skin, and they are also 
found in colostrum and human milk (1, 2).   In colostrum, BCFA have been reported 
up to 1.5%w/w, of fatty acids (FA) with anteiso-17:0 at 0.45%w/w, which is greater 
than the mean concentrations of docosahexaenoic acid (0.32%w/w) and arachidonic 
acid (0.4%w/w) (1). An early study reported more than 50 different BCFA in human 
milk, totaling 1.5%w/w (2), and a more recent study reported a single BCFA, anetiso-
17:0, ranging from 0.12-0.93% of total FA (3).  Thus, BCFA are a natural component 
of breastfed infant intake at levels similar to those fatty acids known to be highly 
bioactive. 
 
BCFA synthesized by human skin (4, 5) comprise 25-30%w/w of vernix FA (6). 
Vernix production by the fetal skin begins at about the mid-way time through normal 
gestation (7) and continues until term birth (8). From early in the third trimester, 
vernix becomes suspended in amniotic fluid (8), and is swallowed by the fetus in 
increasingly large amounts as term birth approaches (8, 9).   We recently showed that 
BCFA are present in meconium of healthy term infants (6), implying that they are 
present throughout the length of the gut.  Moreover, BCFA with fewer than 16 carbons 
were detected in vernix but not in meconium, while BCFA with at least 16 carbons 
were detected in both. This selective shift in BCFA distribution indicates that the fetal 
alimentary canal metabolizes BCFA, suggesting that BCFA play a metabolic role in 
the developing gut.  
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Necrotizing enterocolitis (NEC) is a major cause of morbidity and mortality in 
premature infants (10).  Its pathogenesis is unclear, and no effective prophylactic has 
emerged.  Major risk factors for NEC development are prematurity, enteral feeding, 
abnormal bacterial colonization, and intestinal hypoxia-ischemia (11, 12). Human 
milk is associated with reduced NEC risk compared to formulas (10, 13, 14), most of 
which do not contain BCFA because they contain little to no cow’s milk fat.  The 
incidence of NEC drops as gestational age approaches normal term (15), consistent 
with the increase in BCFA gut exposure from ingested vernix.  We speculate that 
development of NEC is related to the absence of BCFA, either from vernix, breast 
milk, or both.  
 
In this study, we test the hypothesis that a pure BCFA mixture reduces the incidence 
of NEC in an established experimental model of NEC.  A mixture of six iso and 
anteiso -BCFA substituted for 20%w/w of straight chain FA in normal rat pup feeds to 
simulate entry of BCFA via vernix.  Ileal BCFA uptake in phospholipids (PL) and 
gene expression (mRNA) for several inflammation-related cytokines, for intestinal 
barrier-related mucins, and for trefoil factor 3 (TFF3) were measured to shed light on 
possible mechanisms mediating any observed effect.  
 
 
Methods 
Animal model and diets.  The protocol was approved by the Animal Care and Use 
Committee of the University of Arizona (#A-324801-95081) and Cornell University.  
Seventy-three neonatal Sprague-Dawley rats (Charles River Laboratory, Pontage, MI) 
were collected by caesarian section one day before scheduled birth. Pups were 
assigned to one of three experimental  groups: (a) dam-fed (DF, n=12), (b) hand-fed 
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with a rat’s milk substitute formula (NEC, n=35), and (c) hand-fed with rat milk 
substitute prepared with 20%, w/w of BCFA mixture (BCFA, n=23). 
 
The BCFA mixture was composed of six fatty acids obtained in purified, free fatty 
acid form (Larodan Fine Chemicals, Malmo, Sweden) at proportions similar to their 
mean proportions in vernix (6): iso-14:0 (25%), anteiso-15:0 (20%), iso-16:0 (25%), 
anteiso-17:0 (8%), iso-18:0 (10%) and iso-20:0 (12%). These were chosen because 
they represent the central range of BCFA found in vernix and are available 
commercially.  The NEC diet was prepared as described previously (16), except that 
almond oil was used instead of sunflower oil. The BCFA diet was prepared as the 
NEC diet, except that (a) the fat emulsion was prepared as described by Baguma-
Nibasheka (17), but with BCFA added such that the complete diet contained 20% w/w 
BCFA, and (b) soy oil was added instead of almond oil.  The FA composition of the 
NEC and BCFA diets is shown in Table 2.1.  Oleic acid (18:1n-9) and linoleic acid 
(18:2n-6) levels differ between the diets, due to the addition of BCFA.  Each pup from 
the NEC and BCFA groups received a total of 850 µl of diet per day.  
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Table 2.1. Fatty acid composition (%w/w) of rat milk substitute (NEC), and rat milk 
substitute with BCFA (BCFA). 
Fatty acids NEC BCFA 
10:0 1.2 1.0 
12:0 1.5 1.4 
iso-14:0 0.1 4.9 
14:0 4.8 4.8 
14:1n-5 0.5 0.5 
anteiso-15:0 0.2 3.9 
15:0 0.5 0.5 
iso-16:0 0.1 5.1 
16:0 19.5 16.8 
16:1 1.0 0.8 
anteiso-17:0 0.2 1.6 
17:0 0.3 0.3 
iso-18:0 n.d.* 1.9 
18:0 8.5 8.0 
18:1n-9 30.7 21.5 
18:2n-6 27.1 20.8 
iso-20:0 n.d.* 2.5 
18:3n-3 3.3 3.1 
20:0 0.5 0.5 
22:0 0.2 0.2 
*n.d.- not detected 
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NEC induction. NEC was induced in all groups according to existing methods (18, 
19). Briefly, pups were exposed to a hypoxia challenge in 100% nitrogen gas twice 
daily for 1 min, followed by hypothermia-exposure at 4°C for 10 minutes.  Pups were 
observed for signs of NEC, specifically abdominal distention, respiratory distress, and 
lethargy.  Animals that developed signs of distress or imminent death before the end of 
the study were terminated and included in the study analysis. After 96 hours, all 
surviving pups were euthanized by decapitation.  Animals expiring during the study 
were excluded from analysis.  
For microscopic evaluation, 2 cm of distal ileum were removed after termination, 
fixed in 70% ethanol, embedded in paraffin and stained with hematoxylin and eosin in 
4-6 m sections.  A histopathologist masked to the treatments assessed and graded the 
histological changes using intestinal injury scores developed previously (20): Grade 0, 
normal ileum; Grade 1, mild damage, slight submucosal and/or lamina propria 
separation; Grade 2, moderate to severe separation of the submucusa and/or lamina 
propria and/or edema in the submucosal and muscular layers, partial loss of villous 
sloughing; Grade 3,  severe separation of the submucosa and/or lamina propria region, 
villous sloughing and initial villus necrosis; Grade 4,  necrosis and loss of villi 
structure and/or transmural necrosis. Typical picture of these scores are shown in 
Figure 2.1. Half grade increments (+0.5, 1.5, 2.5 and 3.5) were used to more 
accurately assess levels of ileal damage.  Animals with histological scores of grade 2 
or more were considered to be NEC positive; this value is used because normal dam-
fed animals which never develop NEC always are scored below this level.  In addition, 
ileal tissue samples (20-35 mg) were collected from the NEC (n=4) and BCFA (n=3) 
groups for FA analysis of the PL fraction. 
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Figure 2.1 Histological scoring system of the terminal ileum of the neonatal rats. 
Histological changes were graded as follows: Score 0 – normal ileum; score 1 – mild 
damage with slight submucosal and/or lamina propria separation; score 2 – moderate 
to severe separation of submucosa and/or lamina propria, and/or edema in submucosal 
and muscular layers, partial villous sloughing; score 3 - severe separation of 
submucosa and/or lamina propria, region villous sloughing and initial villus necrosis; 
score 4 – necrosis and loss of villi structure and/or transmural necrosis.  
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RNA preparation & reverse transcriptase (RT) and real-time PCR.   Total RNA was 
isolated from ileal tissue (snap frozen in liquid N2) using the RNAeasy Plus Mini Kit 
(Qiagen, Santa Clarita, CA) as described in the manufacturer’s protocol. Samples were 
incubated with RNase-free DNAse (20U/reaction) for 10 minutes at 37°C to eliminate 
DNA contamination. RNA concentration was quantified by ultraviolet (UV) 
spectrophotometry at 260 nm, and the purity was determined by the A260/A280 nm 
absorbance ratio (SPECTRAmax PLUS, Molecular Devices, Sunnyvale, CA). RNA 
integrity was verified by gel electrophoresis on a 1.2% agarose gel containing 
formaldehyde (2.2 mol/L) and ethidium bromide in 1X MOPS buffer [(40mM MOPS 
(pH 7.0), 10mM sodium acetate and 1 mM EDTA (pH 8.0)].   
 
RT and real-time PCR assays were performed to quantify steady state mRNA levels of 
selected cytokines (IL-10, IL-18, IFN-γ, TNF-α, TGF-β), mucins (Muc 2, Muc 3, Muc 
4) and trefoil factor 3 (TFF3). cDNA was synthesized from 0.5 μg of DNase-treated 
total RNA. Primers and probes were designed using Primer Express SoftwareTM 
(Applied Biosystems, Foster CA). Target probe was labeled with fluorescent reporter 
dye FAM.  Probe sequences are available upon request.  Reporter dye emission was 
detected by an automated sequence detector combined with ABI Prism 7700 Sequence 
Detection System® software (Applied Biosystems). Real time PCR quantification was 
then performed using TaqMan® 18S controls. 
 
FA analysis.   Dietary lipids were extracted according to a modified Bligh and Dyer 
method (21). Ileal samples were homogenized in methanol with 0.05% BHT: 
chloroform (2:1, v:v). The homogenate lipids were extracted and loaded on thin layer 
chromatography plates (Silica gel G, 20x20, Analtech, Inc. DE). Plates were 
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developed half -way in hexane:diethyl-ether:acetic acid (40:60:1, v:v:v), allowed to 
dry, and re-developed entirely, in the same direction, with heptane:diethyl-
ether:formic acid (80:20:1.8, v:v:v). The separated lipid class bands were visualized in 
iodine vapor and the PL fraction was collected. Fatty acid methyl esters (FAME) for 
dietary lipids and ileal PL were prepared using 14% BF3 in methanol (Sigma 
Chemical, St. Louis, MO). 
 
FAME analyses were performed using a Hewlett Packard 5890 Gas Chromatography-
Flame Ionization Detector (GC-FID). A BPX-70 column (25m × 0.22mm × 0.25µm, 
SGE, Austin, Tx) was used for the analysis with H2 as the carrier gas.  FAME 
identities were determined by electron impact mass spectrometry (MS), using a Varian 
Star 3400 GC coupled to a Varian Saturn 2000 ion trap MS. FAME identities were 
based on GC retention time of each substance and their electron impact mass spectra. 
An equal weight FAME mixture (68A; Nuchek Prep, Elysian, MN) was used to 
calculate response factors. The following pure BCFA were also used as a reference: 
iso-14:0, anteiso-15:0; iso-16:0, anteiso-17:0, iso-18:0 and iso-20:0 (Larodan Fine 
Chemicals AB, Malmo, Sweden). FA levels are expressed as %, weight for weight 
(%w/w).  
 
Statistics.  The Chi-Square test was used to analyze differences in incidence of NEC. 
ANOVA followed by Fisher PLSD (StatView for Macintosh, Abacus Concepts, Inc., 
Berkely, CA) was used to analyze differences in cytokine gene expression. Tukey 
LSD, (JMP 8, SAS Institute, Cary, NC) was used to investigate differences in weights 
between the groups. 
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Results 
The overall average survival rate was 89% (65/73).  It was similar among the groups, 
with 87% (13/15), 89% (31/35), and 91% (21/23) in the DF, NEC and BCFA groups, 
respectively.    Body weights at the end of study were 8.06 ± 0.24, 5.97 ± 0.05, and 
5.69 ± 0.10g (mean ± SEM) for the DF, NEC and BCFA groups, respectively. There 
were no significant differences between the NEC and BCFA groups. The high relative 
weight of DF pups compared to the artificial feeding groups was similar to previous 
studies (20, 22, 23).  
 
Figure 2.2 shows the histological NEC scores (A) and the incidence of NEC (B) in the 
experimental groups.  Pups in the DF group do not normally develop NEC and no pup 
in the present study exhibited an abnormal intestinal architecture.  In the NEC group, 
17 of 31 (55%) of pups had a score of 2 or greater indicating NEC injury.  In contrast, 
the BCFA group had histological scores of 2 or greater in 5 of 21 pups (24%).  The 
difference in NEC development between NEC and BCFA groups was statistically 
significant (p<0.05), indicating that BCFA substituted for conventional fat reduced the 
incidence of NEC by 56% (55% vs 24%).  
 
 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Histological scores (A) and incidence of necrotizing enterocolitis (NEC) 
(B) in the different treatment groups. DF- dam- fed pups, n=13; NEC- pups fed a rat 
milk substitute, n=31. BCFA- pups fed a rat milk substitute with BCFA, n=21. 
Animals were considered having NEC if their histological score was ≥ 2; *p<0.05. 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
H
is
to
lo
g
ic
a
l 
N
E
C
 s
co
re
A
0
10
20
30
40
50
60
DF NEC BCFA
In
ci
d
en
ce
 o
f 
N
E
C
 (
%
)
*
B
36 
BCFA uptake by rat ileum. Figure 2.3 presents BCFA concentrations (%w/w; mean 
± SD) in ileum PL fraction of 3 pups without NEC from the BCFA group. BCFA were 
taken up by the ileum and were incorporated in the ileum PL. Furthermore, BCFA 
were incorporated in a selective manner in the PL: iso-14:0 and anteiso-15:0 were 
selected against and iso-18:0 was enriched in PL, compared to their proportions in the 
diet. Concentrations of BCFA in the ileum PL fraction of the NEC group were 
negligible (data not shown). The profile of other, non-branched FA in ileum PL was 
similar in the two hand-fed groups (data not shown).     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Branched chain fatty acid (BCFA) concentrations (%w/w) in BCFA diet 
and in ileum phospholipids (PL) of pups fed BCFA diet (n=3; mean ± SD). i=iso; 
ai=anteiso  
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Cytokine, mucin, TFF3 mRNA.   Table 2.2 presents results for selected mean ileal 
cytokine mRNA levels, expressed as multiples of the value found for the DF group. 
IL-10 levels were more than three-fold greater in the BCFA group compared to the DF 
and NEC groups. TGF-β levels in the BCFA and NEC groups were the same, and both 
were significantly lower than the DF group. IL-18 and TNF-α mRNA were 
significantly higher in the BCFA group compared to the DF group. IFN-γ levels in the 
BCFA group did not differ significantly from the DF group, but levels in the NEC 
group were significantly lower than the DF group.  
 
Mean Muc2, Muc3, Muc4 and TFF3 mRNA levels, expressed as multiples of the 
value found for the DF group are also presented in Table 2.2.  No differences in Muc3 
and TFF3 mRNA among the experimental groups were observed; mRNA of the Muc2 
and Muc4 mRNA were similar in the artificial feeding groups.    
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Table 2.2 Cytokine, mucin (Muc), and trefoil factor 3 (TFF 3) mRNA levels in ileum 
of neonatal rats (mean ± SEM)  
 DF NEC BCFA 
IL-10 1.0 ± 0.1 1.0 ± 0.1 3.2 ± 1.5* 
TGF-β 1.0 ± 0.1 0.7 ± 0.1† 0.7 ± 0.1† 
IL-18 1.0 ± 0.1  1.3 ± 0.1 1.7 ± 0.1
†
 
TNF-α 1.0 ± 0.1 2.4 ± 0.8 2.7 ± 0.7† 
IFN-γ 1.0 ± 0.3 0.4 ± 0.1† 0.7 ± 0.4 
    
Muc 2 1.0 ± 0.1  0.5 ± 0.1
†
  0.4 ± 0.1
†
 
Muc 3 1.0 ± 0.1 1.6 ± 0.3 1.2 ± 0.2 
Muc 4 1.0 ± 0.1 0.3 ± 0.8
†
 0.1 ± 0.1
†
 
TFF 3 1.0 ± 0.1 1.3 ± 0.2 1.6 ± 0.2 
 
Mean steady-state mRNA levels for the dam-fed group (DF) 
were assigned a value of 1 and mean mRNA levels from pups 
fed rat milk substitute (NEC) or rat milk substitute with 
BCFA (BCFA) are expressed as fold changes relative to this value. 
n=10-23 pups per treatment. 
*p<0.05 vs. NEC and vs. DF 
†
p<0.05 vs. DF 
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Discussion 
BCFA are constituents of the GI tract of normal, healthy, term newborns (6).  The 
BCFA chain length distribution in vernix is from about C11 to C26, while that of 
meconium is from C16 to C26.  Moreover, most BCFA entering the GI tract as 
amniotic fluid-suspended vernix disappear into the GI tract and do not appear in 
meconium.  In the present study we show that oral administration of BCFA 
significantly reduces the incidence and severity of NEC in a neonatal rat model. 
Importantly, BCFA from the diet are taken up by the ileum in vivo and incorporated in 
a structure-selective manner into the PL fraction of the ileum. Selection against shorter 
chain BCFA (<16 carbons) for incorporation into the PL fraction is consistent with our 
previous observation on the systematic shift of BCFA distribution between human 
vernix and meconium (6).  These results demonstrate that BCFA are not inert 
components of the GI tract or used exclusively for energy, but are selectively 
incorporated into membrane lipids mediated by enterocytes. 
 
The reduction in NEC incidence is similar compared to most prophylactic treatments 
targeting NEC in experimental studies (24-26). We speculate that altered membrane 
composition may change enterocyte resistance to the as-yet ill-defined initiating 
events associated with NEC. Moreover, the entry and possible accumulation or 
turnover of BCFA could signal that normal parturition is approaching, in analogy to 
blood cortisol.  This speculation is intriguing in part because amniotic fluid suspended 
lung surfactant phospholipids appear to have a role in vernix particle entry into the 
amniotic fluid (8). 
 
Changes in selected mRNA levels suggest possible mechanisms of BCFA protection 
against NEC.  There is no obvious overall trend in inflammatory cytokine mRNA with 
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and without BCFA treatment.  A specific, notable change is the increase in ileal IL-10 
mRNA caused by BCFA relative to the NEC group.  Properties of IL-10 in intestinal 
disease apparently related to anti-inflammatory action have been reported. An IL-10 
knockout mice spontaneously develops chronic enterocolitis throughout the entire 
intestinal tract (27); administration of IL-10 prevents the development of 
inflammatory bowel disease (IBD), and it was suggested that IL-10 treatment can 
counteract effectors involved in intestinal lesions  in these animals (28). A similar 
effect was previously reported in studies with epidermal growth factor (EGF) and 
maternal milk in a rat NEC model (23, 29). Protective effect of EGF against NEC was 
associated with 3-fold increase in ileal mRNA IL-10 (29).  Likewise, reduced NEC 
incidence in rat-milk-fed versus formula-fed pups was associated with more than 
doubled ileal IL-10 mRNA levels (23). Others showed that subcutaneous 
administration of recombinant human IL-10 to NEC-induced (hypoxia) neonate rats 
reduced the severity of microscopic ileal lesions compared to untreated rats  (30).  
Taken together, elevated ileal IL-10 mRNA in the current study is consistent with the 
hypothesis that it mediates NEC reduction in the BCFA group, possibly by 
counteracting pro-inflammatory effects of elevated TNF-α and IL-18 mRNA.  
 
Our and other laboratories have shown that proinflammatory cytokines are important 
factors in NEC pathogenesis (29, 31, 32). Caplan et al (33) found high plasma levels 
of TNF-α in infants with NEC, but no correlation was observed between TNF-α levels 
and severity of the disease.  In the present study, we have found that ileal gene 
expression of TNF-α is significantly increased in the NEC group compared with 
healthy controls. However, the BCFA treatment of NEC did not affected TNF-α 
mRNA levels in the site on injury.  Levels of IFN-γ mRNA were significantly lower in 
the NEC group compared to DF but the BCFA group was not different. The 
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relationship of IFN-γ in NEC is ambiguous.   Elevated intestinal IFN-γ levels have 
been reported in NEC patients (34), however no significant differences in IFN-γ were 
found between formula-fed-hypoxic NEC rats and non-hypoxic formula-fed groups 
with mild intestine damage in a study similar to ours (35) and in separate studies ileal 
IFN-γ mRNA was not related to neonatal rat pups NEC development (31).   
 
Another mechanism by which BCFA may also protect against NEC is by improving 
the intestinal barrier against pathogens. Intestinal mucins and  TFF3 participate in host 
defense mechanisms against microbial invasion (18) .  No differences in TFF3 mRNA 
among the study groups were observed, and levels of mucin mRNA were similar in 
the NEC and BCFA groups, providing no evidence for alterations in barrier function.   
 
Alternatively, BCFA may protect against NEC by establishing balanced and diverse 
intestinal flora. Abnormal gut colonization is a risk factor for NEC (11, 12). The 
establishment of bifidobacteria, the predominant commensal strain in breast fed term 
infants, is delayed and less abundant in preterms (36). BCFA are prominent membrane 
components of many bacterial species (37), and many bifidobacteria include BCFA at 
various levels (0.6-24%w/w). Iso-14:0 is the second most abundant FA in 
bifidobacterium breve, with levels as high as 24.6%w/w (38). BCFA in the fetal and 
neonatal gut may influence flora development by favoring the growth of commensal 
organisms, and deserves attention in future studies. 
 
In conclusion, BCFA reduce the incidence of NEC by 56% in a neonatal rat pup 
model.  Of the various outcomes measured, 3-fold increased ileal levels of the anti-
inflammatory IL-10 cytokine in the BCFA-fed group has been previously linked to 
reduced bowel disease and may have mediated the effect.  We did not measure the 
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establishment of commensal flora, however previous work shows that 
supplementation with a probiotic mix induced production of IL-10 by intestinal 
mucosa of patients with acute pouchitis (39), and lactobacillus species prevented 
colitis in IL-10 gene deficient mice (40). Future research will examine how BCFA 
might reduce NEC by affecting diversity and composition of intestinal flora.  
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CHAPTER 3 
 
BRANCHED CHAIN FATTY ACID COMPOSITION OF RETAIL COW’S 
MILK* 
abstract 
Milk and other dairy products contribute significant amounts of FA to the average 
American's overall daily FA intake. The fatty acid profile of milk gained attention due 
to (a) its overall saturated fat content, associated with coronary heart disease, and (b) 
individual fatty acids, such as conjugated linoleic acid, associated with potential health 
benefits.  Branched chain fatty acids (BCFA), are a class of primarily saturated fatty 
acids with a methyl branch or more on the carbon chain. BCFA profiles and levels in 
cow’s milk in response to different diets and supplementations have been reported. 
Their distribution in retail milk in the United States, however, has not been reported.  
BCFA are found in trace levels in non-ruminant tissues, but they are a major 
component in vernix. Vernix, suspended in amniotic fluid, is normally swallowed by 
the fetus, thus introducing BCFA into the newborn intestinal gut. This indicates that 
humans are exposed to BCFA from a very early age. BCFA are also found in human 
milk, continuing the supply of BCFA. Although BCFA from the iso- and anteiso- type 
were not investigated in relation to human health, evidence suggests a beneficial role 
of these BCFA in in vitro and in vivo models. As data on possible beneficial effects of 
BCFA on human health start to emerge, information on their concentrations in retail 
milk becomes valuable. Our aim was to investigate the profile and levels of BCFA in 
retail whole milk in the United States.  Methods: Whole fluid milk samples, packed 
 
* Ran-Ressler RR, Sim, D, O’Donnell AM, Bauman DE Branched chain fatty acids 
composition of retail cow’s milk. Submitted to the Journal of Dairy Science, August 2010. 
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for transport to retail stores, were obtained from 56 processing plants across the 
contiguous 48 United States. Milk samples were conventionally produced. Milk 
samples were shipped on ice overnight to Cornell University and immediately 
processed for FA analysis.  Fatty acids were extracted with conventional methods and 
were analyzed using gas chromatography coupled with mass spectrometry.  
Results and discussion: Retail milk samples contain BCFA with 14-18 carbons, and all 
the BCFA were from the iso- and anteiso- configuration. BCFA with fewer than 14 
carbons and multi-methyl BCFA such as phytanic acid and pristanic acid were not 
detected. Levels of the total BCFA were 2.05 ± 0.14 (%w/w; mean ± SD), and BCFA 
from the anteiso- configuration comprised more than half of the total BCFA. An 
estimation of BCFA consumption from retail milk was calculated. It was concluded 
that BCFA may contribute a substantial amount of the daily fat intake, in amounts 
exceeding intake of some of the n-3 long chain fatty acids.  
 
 
 
Introduction 
Milk and other dairy products contribute significant amounts of FA to the average 
American's overall daily FA intake.  Cow’s milk fat is characterized by relatively high 
short and medium chain (C12-C16) fatty acids, and low polyunsaturates.  Individual 
fatty acids, such as conjugated linoleic acids (CLA), have a beneficial effect on health 
maintenance and prevention of acute and chronic disease  (1-2).  The fatty acid (FA) 
profile of milk in all species, including cow’s milk, is sensitive to dietary fat intake, 
for instance, concentrate versus pasture versus fish oil supplementation (3-6), thus 
milk composition may differ depending on production practices.  We recently reported 
the composition of major FA retail milk in the United States (US) (7).  About 3 % of 
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FA were unidentified and listed as a group under “Other”; branched chain fatty acids 
(BCFA) are included in this group.   
 
BCFA are primarily saturated FA (SFA) with one or more methyl branches. In human 
metabolism, they are best studied as components of skin lipids.  Overall, several dozen 
specific BCFA, are found in milk and tissue of ruminants, including sheep and goats, 
presumably synthesized by ruminal organisms that rely on them for membrane lipids 
(8-9). BCFA function in the membranes similarly to cis unsaturated double bonds; 
both interfere with the ability of saturated hydrocarbon chains to pack tightly forming 
rigid extended structures.  Old data show that an E. coli strain that lost the ability to 
desaturate saturated FA were restored to wild-type growth rates by the addition of 
BCFA (10).  Many rumen microorganisms, such as Ruminococcus Flavefaciens c1a 
and Fusobacterium sp 9-21  have membranes with high concentrations of BCFA, with 
levels up to 80% of  membrane FA (11).  
BCFA are conveniently categorized as mono- and di-/multi- methyl BCFA; in 
monomethyl BCFA, the predominant branching is at the terminal methyl (iso) or next 
to the terminal methyl (anteiso), as shown in Figure 1.1. iso- and anteiso-BCFA are 
the main BCFA reported in cow’s milk (3-4, 6, 12-13).  Terpenoid BCFA, exemplified 
by internal periodic poly-methyl branching such as phytanic acid (3,7,11,14 tetra-
methyl hexadecanoic acid) and its alpha oxidation product pristanic acid (2,6,10,14 
tetra-methyl pentadecanoic acid) are also reported in cow’s milk (13-14).  
 
Information on human intake and metabolism of BCFA is scant.  We recently showed 
that BCFA are a major component of the late term fetal and newborn gut contents 
(15).  They comprise almost one third of the FA in vernix (15), the white fatty film 
that covers the fetus in utero. Vernix suspended in amniotic fluid is normally 
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swallowed by the fetus, increasingly so as parturition approaches (16), exposing the 
fetal gut to BCFA from an early age. Moreover, BCFA are also found in human milk 
(17-18) where they reportedly comprise 1.5%w/w.  A 1981 report put the 
concentrations of anteiso-17:0 in colostrum at 0.45%w/w, higher than the 
concentrations of docosahexaenoic acid (DHA; 22:6n-3; 0.32%w/w) and arachidonic 
acid (20:4n-6; 0.4%w/w) (18).  A study in rat pups shows that BCFA reduce the 
incidence of necrotizing enterocolitis (NEC), a devastating intestinal disease affecting 
premature infants (Ran-Ressler et al, unpublished data). Thus, BCFA are a major 
component in perinatal nutrition, and although they may have a beneficial role in 
human health, their presence in the US food chain has been almost completely 
neglected. 
 
In a 1994 survey, milk contributed 7.5% of the protein, 4.2% of the total fat, and 
approximately 8% of the total saturated fat in the diet of adults (19). Based on 
NHANES 1999-2004 (20) fluid milk, mostly whole milk, provided 7.5%, and 6.4% of 
energy intake in children age 2-4 and 5-10, respectively.  We hypothesized that BCFA 
are found in retail milk in the US and thus are consumed in substantial amounts in the 
American diet.  We report here the first data on the structure and quantitative analysis 
of BCFA in a representative sample of the US retail milk supply.  
 
 
Methods 
Sampling. Conventionally produced whole fluid milk samples were obtained from 56 
milk processing plants across the contiguous 48 United States. All samples were 
obtained in December, 2008. All samples were homogenized, pasteurized and 
packaged for transport to retail stores. Processing plants were selected based on the 
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criteria that they represented at least 50% of the volume of milk produced in that area. 
Milk was shipped on ice overnight to Cornell University and immediately processed 
for the analysis of FA composition.  
 
Fatty Acids Analysis. Milk fat extraction was based on the Mojonnier method (AOAC 
995.19) as modified by Barbano (21). Briefly, milk fat was obtained from 10 ml whole 
fluid milk by a sequence of 3 successive extractions.  Ten ml of 95% alcohol and 25 
ml ethyl ether plus milk was followed by vigorous mixing, then 25 ml petroleum ether 
was added and followed by vigorous mixing, and decanting of the ether layer. The 
second and third extractions were similar, except the volume of solvents was reduced 
to 5 ml of 95% alcohol and 15 ml each of ethyl and petroleum ethers, and the third 
extraction omitted the 95% alcohol. Ether solutions from the 3 extractions were 
combined, dried and re-suspended in hexane. Methyl esters of the extracted fat were 
prepared using sodium methoxide as the methylation reagent, according to Christie 
(22) as modified by Chouinard (23). 
 
Fatty acid methyl ester (FAME) analyses were performed using a Hewlett Packard 
5890 Gas Chromatograph (GC) with flame ionization detector. A BPX-70 column 
(25m × 0.22mm × 0.25µm, SGE, Austin, TX) was used for the analysis with H2 
carrier gas.  The oven program was initially 80°C for one minute, increased 30°C per 
minute to 170°C and held for two minutes, then increased by 10°C per minute until a 
final temperature of 240°C held for one minute. 
 
FAME identities were determined by electron impact mass spectrometry (MS), using a 
Varian Star 3400 GC coupled to a Varian Saturn 2000 ion trap MS, based on GC 
retention times and electron impact mass spectra. An equal weight FAME mixture 
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(68A; Nuchek Prep, Elysian, MN) was used to calculate response factors.  Several 
pure BCFA were also used as reference standards: iso-14:0, anteiso-15:0; iso-16:0, 
anteiso-17:0, iso-18:0 and iso-20:0 (Larodan Fine Chemicals AB, Malmo, Sweden). 
FA levels were expressed as weight % for all FA.  Under these conditions, two pairs 
of FAME coelute, iso-15:0/14:1 and iso-17:0/16:1.  GC with covalent adduct chemical 
ionization tandem mass spectrometry (CACI-MS/MS) was used to resolve the two sets 
of overlapping peaks (24).  Solutions of pure 14:1, 15:0, 16:1, and 17:0 FAME (0.5 
μg/μl, Nucheck Prep Inc, Elsyian, MN) were used to determine response factors for 
ions characteristic of the respective FAME.  Selected characteristic ions were plotted 
to resolve and quantify co-eluting FAME.  MH
+
 was used for the iso-FAME in the 
milk sample, and the sum of [MH-32]
+
, MH
+
, and [M+54]
+
 intensities were used 
applied to monounsaturated FAME.  The relative percent contribution of the two 
interfering FAME was applied to the coeluting peaks to produce yield pure intensities. 
 
 
Results and discussion 
BCFA in Retail Milk. Figure 3.1 presents in summary form the major classes of FA 
found in the present retail milk samples.  The sum of palmitic acid (16:0) and all other 
saturated FA (SFA) with shorter chain lengths comprised about 51%w/w (mean), 
saturated FA with 18 or more carbons were 12%.  These values were within 
experimental error of those reported previously for our similar comprehensive retail 
milk sampling.  Monounsaturated FA (MUFA) were about 30% and polyunsaturated 
FA (PUFA) were 4.7%, again within experimental error of previously reported 
composition.   
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Figure 3.1.  Fatty acid composition (%w/w; mean ± SD; n=56) of conventional whole 
milk samples. Fatty acids were grouped as follow:  branched chain fatty acids  
(BCFA); de-novo synthesized saturated fatty acids, including 16:0 (≤ 16:0);  saturated 
fatty acids longer then 16:0 (>16:0); monounsaturated fatty acids ( MUFA); 
polyunsaturated fatty acids (PUFA). 
 
BCFA comprised a total of 2.05 ± 0.14% of FA, or most of the 3% of FA listed 
previously as “other” (7).  The mean BCFA levels reported in the present study fall 
within the range previously reported in studies that measured cow’s milk FA in 
response to various diets in small scale experimental studies (3-5, 8, 12).   
 
Table 3.1 presents the mean proportions of BCFA in retail milk as %w/w of total and 
as a % of total BCFA (Mean ± SD). BCFA with 14 to 18 carbons and iso- or anteiso- 
configuration were detected, and no BCFA with multiple branching were found.  Four 
iso-C14 to iso-C17 were detected in all samples; iso-18:0 was also detected in most 
but not all of the samples.  anteiso-15:0 and anteiso-17:0 were the only anteiso BCFA 
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found.  They were in comparable concentration and constituted more than half of the 
total BCFA detected.  
 
 
Table 3.1. Branched chain fatty acids (BCFA) in retail milk expressed as %w/w of 
total fatty acids and as % of BCFA (n=56; mean + SD). 
 
BCFA Total FA  BCFA
 
 
iso-14:0 0.13 ± 0.04 6.4 ± 1.4 
iso-15:0 0.13 ± 0.01 6.6 ± 0.4 
anteiso-15:0 0.56 ± 0.03 27.5 ± 1.3 
iso-16:0 0.31 ± 0.03 14.9 ± 0.9 
iso-17:0 0.26 ± 0.02 12.7 ± 0.7 
anteiso-17:0 0.61 ± 0.06 29.9 ± 2.0 
iso-18:0 0.04 ± 0.02 1.9 ± 0.9 
   
 
    
BCFA with fewer than 14 carbons, such as iso- and anteiso- 13:0, were not detected in 
any of the samples.  Both iso- and anteiso-13:0 BCFA in cow’s milk have been 
reported by some (3, 5, 8, 13) but not by others (4, 6, 25).  Retail milk is obtained from 
dairies that pool milk from many farms, and it is possible that specific feeds on some 
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farms support ruminal C13 BCFA more than on other farms, and thus small amounts 
may be diluted to below detection limits (12, 26).    
 
Neither phytanic acid, a product of released phytol from chlorophyll by rumen bacteria 
(27), nor its peroxisomal oxidation product pristanic acid (28), were detected in the 
retail milk.  As with C13 BCFA, these terpenoid BCFA were reported to be present in 
bovine milk by some (13-14) but not by others (3-6). When reported, the variance of 
these BCFA was high, and it was suggested (14) that differing feed compositions are 
responsible for variable terpenoid metabolizing ruminal bacteria.  As with the case of 
iso- and anteiso- 13:0, it is possible that minor amounts of phytanic and pristanic acid 
were present, but diluted to below detection limits. 
 
For comparison with bioactive FAs found primarily in dairy products, rumenic acid 
(cis-9, trans-11-18:2), the most concentrated conjugated linoleic acid (CLA) in cow’s 
milk, was 0.57%, in conventionally produced retail milk.  Vaccenic acid (trans-11-
18:1), the most concentrated trans monoene in cow’s milk, was 1.45% in U.S. retail 
milk, and the sum of all trans FA was about 3% (7).  Thus, both anteiso BCFA are at 
greater concentration in milk fat than rumenic acid, and total BCFA is more than half 
the concentration of total trans- FA.    
 
Estimated human BCFA intake from retail milk. We can estimate the contribution of 
BCFA to the nutrition of Americans based on measured and estimated intake of milk.  
One cup (244 g = 8 oz) of whole milk (3.25% milkfat) contains 7.9 g fat (29),   2% of 
7.9 g yields a total of 158 mg BCFA per cup whole milk.  For comparison to intake of 
bioactive FA in the American diet, this value is greater than the 100 mg average daily 
consumption of the DHA and eicosapentaenoic acid (EPA) reported in a survey of 
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8604 Americans between 1999 and 2000 (30) and by women of child bearing age 
based on NHANES III data  (31).   
 
In some population groups, such as small children, milk consumption can be higher: 
consumption by small children of 2.6 servings of milk was reported recently (32); 
most of the children in the study consumed whole milk. This consumption would thus 
provide 412mg BCFA daily, which would provide almost 1% of the total fat intake of 
children age 2-5 (33).  It thus appears that the absolute amount of daily intake of 
BCFA from milk--even more so, the amount of BCFA consumed per kilogram body 
weight--will be higher in some populations, such as in small children.  
 
Apart from milk, other foods produced by ruminant animals, specifically cheese and 
beef, are expected to be other primary contributors of BCFA to the diet.  US cheese 
BCFA can be estimated from the present measures of milkfat BCFA of about 2% of 
FA.  BCFA averaged about 2%, w/w in Canadian retail beef (34), and similar to 
Malaysia beef tallow with C13-C20 BCFA with mean concentration 2.3% (mutton 
tallow had 4.0% BCFA) (35).  We assume American beef has the same 2% BCFA 
levels  as in Canada, and an average 28% and about 18% fat content in cheese and in 
beef, respectively (29). According to economic disappearance data adjusted for loss, 
American’s average per capita consumption of cheese is 30 g (1.1 oz) per day (36); at  
about 28% fat on average and at about 2% BCFA, cheese contributes 168 mg of 
BCFA per day. Similarly, Americans consume 50 g (1.8 oz) of cooked beef per day 
(36); at  about 18% fat and about 2% BCFA, beef contributes about 180 mg of BCFA 
per day.  Table 3.2 presents these values summed to estimate total current per capita 
intake of BCFA of about 400 mg per day from the most common ruminant foods. 
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We also consider the implications of dietary guidelines on BCFA consumption (37). 
Americans are advised to consume three servings from the milk group, where a 
serving, for example, is equal to 1 cup of milk or yogurt and 1.5 oz (42 g, 2 slices) of 
cheese.  For simplicity we assume this to be represented by the present average dietary 
pattern of milk intake in the US, which is 31% whole milk, 39% low fat (2%) milk, 
14% lower fat (1%) milk, with the balance nonfat milk (36).  Using these values we 
estimate a weighted sum of the total BCFA intake from three servings of milk and 
cheese to be nearly 400 mg.  Meat, cheese and milk together account for an average 
estimated intake of about 575 mg BCFA per capita per day (Table 3.2).  
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Table 3.2.  Estimated mean daily branched chain fatty acids consumption per capita in the 
US
1
, based on actual and recommended
2
 consumption of milk, cheese and beef 
 
 Actual
2
 Recommended
2
 
Food 
Portion 
(g) 
BCFA
3
 
(mg) 
Portion 
(g) 
BCFA
3
 
(mg) 
Milk
4
 119 54 215 98 
Cheese
5
 30 168 53 297 
Beef
6
 50 180 50 180 
Total 199 402 318 575 
1
Intake is based on (36)     
2
Actual consumption reflects the current 
consumption from milk, cheese and beef by Americans, which falls below 
recommended levels from the milk food group (36). Recommended 
consumption represents the levels of BCFA consumption that would obtain if 
Americans were to consume recommended amounts from the milk food group, 
keeping the same existing patterns as the actual consumption. For beef, the 
actual consumption was considered as the recommended one. Thus, the same 
value for beef was used for both. 
3
 BCFA  - branched chain fatty acids               
4
 Mean, per capita, milk consumption, based on the proportions currently 
consumed by Americans of 3.25%, 2%, and 1% milk (36)     
5
Cheese types are 
the main cheeses consumed by Americans (36). An average of 28% fat was 
used for estimation (29). Amounts are based on patterns of current 
consumption of cheese (36).      
6
 For cooked beef, an average of 18% fat was 
used for estimation (29).  Americans consume enough from the meat food 
group, thus the actual and the recommended consumption were the same.   
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Use of 2 cups of whole milk in place of reduced or no fat milks and consuming 1 
serving of cheese ( 42gr, 1.5oz)  would bring total BCFA to 731 mg/day (316 mg from 
milk + 235 mg from cheese + 180 mg from beef). These consumption levels, then, 
would be higher than the 500mg/d intake for DHA and EPA for the general population 
recommended by the American Dietetic Association (38), and more than double the 
300 mg/d of DHA and EPA recommended by the World Health Organization in 
pregnancy and lactation (31). 
 
These estimates show that daily BCFA intake is substantial and that current 
recommendations promote an increase in present intake, considerably high than other 
bioactive FA.  Unlike DHA and EPA, for instance, BCFA sources include a greater 
variety of common food items, principally products of ruminants, regularly consumed 
by non-vegans.  The low level of interest in BCFA nutrition is remarkable considering 
their long-standing intake.  
 
The American dietary guidelines recommend consumption of low fat dairy products, 
however studies provide no convincing evidence that increased whole milk 
consumption is harmful with respect to ischemic heart disease and ischemic strokes 
(39). Some studies provide evidence that higher consumption of whole fat compared 
to reduced fat milk was associated with lower body mass index in preschool- and 
elementary school-age children and less weight gain in adults (32, 40-41) and with 
lower incidences of anovulatory infertility (42). Thus, the emergence of potential 
benefits of whole milk consumption may have a significant effect on BCFA intake in 
the US population, increasing BCFA consumption even more. 
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BCFA are synthesized in large amounts by human skin (44), comprise 29%w/w, of the 
FA in vernix and are normal constituents of the healthy newborn gut (15). A 
systematic shift in BCFA profile was observed between vernix and meconium of the 
same infant, implying that the fetal alimentary canal selectively metabolizes BCFA. In 
very recent work, anoxic rat pups fed a mixture similar to most BCFA found in the 
retail milk samples (iso-14:0, anteiso-15:0, iso-16:0, anteiso-17:0, iso-18:0, and iso-
20:0) in rat milk substitute, had reduced the incidence of NEC compared to a control 
group (Ran-Ressler et al, unpublished data) and elevated mRNA levels of the 
intestinal, anti-inflammatory cytokine IL-10.  BCFA are selectively incorporated into 
phospholipids of rat pup ileum and into human Caco-2 cells (45). The risk reduction in 
NEC development may be linked to these observations.  Apoptotic properties of 
BCFA on human breast cancer cells are structure-specific, with iso-16:0 having the 
highest activity among BCFA of C12-C20 (46).  iso-15:0 inhibited tumor growth in 
cultured cells and in an in vivo (mice) models with no obvious deleterious effects (47).  
Thus, BCFA of the type found in U.S. retail milk may have a beneficial effect on 
proper tissue function and on gut development and function. 
 
 
In conclusion, we document for the first time the profile and amounts of BCFA in 
retail whole milk in the U.S. Milk BCFA have chain lengths of 14 to 18 carbons and 
include both iso- and anteiso- BCFA. BCFA comprising 2.05%w/w of the FA in retail 
whole milk, and along with estimated BCFA levels in beef and estimated per capita 
intakes can amount to a levels higher than many bioactive FA. BCFA are readily 
available from food consumed by healthy individuals in the US.  Their importance in 
the U.S. food supply and bioactivity suggest that they should be more carefully studied 
for their biological effects. 
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